Breast cancer stands as a significant health crisis for women globally, and alarmingly, it has become the leading cause of cancer-related deaths among Mexican Women since 2006. This devastating disease accounts for 15% of all cancer fatalities in this demographic and is the second leading cause of mortality for women aged 30-54 in Mexico. The situation is further exacerbated by a mortality-to-incidence ratio twice as high as that in the United States, highlighting a critical disparity in breast cancer outcomes. Predictions estimate that in a single year, over 23,000 Mexican women would be diagnosed with breast cancer, with nearly 6,600 succumbing to the disease. Adding to the complexity, the average age of breast cancer diagnosis in Mexico is a decade younger than in many developed nations, around 50 years old.
Compounding these challenges is the disproportionately high prevalence of triple-negative breast cancer (TNBC) among Mexican women. This aggressive subtype, known for its rapid growth and limited treatment options, constitutes a staggering 23% of all breast cancer cases in Mexico. This figure dramatically contrasts with countries like Canada, where TNBC accounts for approximately 11% of cases. Understanding the factors driving this elevated rate of TNBC in Mexican women is crucial for developing targeted prevention and treatment strategies.
Among the critical factors influencing breast cancer risk, particularly for the triple-negative subtype, are mutations in the BRCA1 and BRCA2 genes. These genes play a vital role in DNA repair, and mutations can significantly increase the susceptibility to breast and ovarian cancers. While BRCA testing is increasingly recognized as essential for personalized breast cancer management, its accessibility in Mexico remains limited. Genetic counseling and testing services are not widely available, hampered by the high costs and lack of public insurance coverage. This scarcity of resources, coupled with limited awareness among healthcare providers about the benefits of genetic risk assessment, creates substantial barriers for Mexican women seeking to understand their genetic predisposition to breast cancer.
Recognizing this gap, a groundbreaking study was conducted to investigate the prevalence of BRCA mutations in young Mexican women diagnosed with triple-negative breast cancer. This research, carried out at a major cancer center in Mexico City, aimed to provide crucial data to inform clinical practice and healthcare policy in Mexico. By focusing on this high-risk population, the study sought to determine the frequency of BRCA1 and BRCA2 mutations and identify specific genetic patterns that could be leveraged for more effective screening and treatment strategies for Mexican women facing breast cancer. The findings of this study have profound implications for understanding breast cancer risk in Mexican women and underscore the urgent need to improve access to genetic services and tailored healthcare interventions.
Understanding Breast Cancer in Mexican Women
The statistics surrounding breast cancer in Mexican women paint a concerning picture, highlighting the urgent need for targeted interventions and improved healthcare access. As the leading cause of cancer-related death for this demographic, breast cancer surpasses even cervical cancer, which was historically the most prevalent cancer among women in Mexico. The high mortality rate, coupled with a relatively younger age of diagnosis, underscores the aggressive nature of the disease in this population and the potential impact of factors such as delayed diagnosis and limited access to optimal treatment.
Compared to women in the United States and Canada, Mexican women are often diagnosed with breast cancer at later stages, contributing to poorer outcomes. This delay can be attributed to various factors, including lower rates of mammography screening, limited awareness of breast cancer symptoms, and barriers to accessing timely and quality healthcare services. Furthermore, the healthcare infrastructure in Mexico faces challenges in providing widespread access to advanced diagnostic tools and treatments, particularly in rural and underserved communities.
Adding to these complexities is the higher proportion of triple-negative breast cancer among Mexican women. TNBC is known to be more aggressive and challenging to treat than other breast cancer subtypes. Its triple-negative status means that it lacks the three common receptors (estrogen receptor, progesterone receptor, and HER2) that are targeted by many hormonal and targeted therapies. This leaves chemotherapy as the primary systemic treatment option, which can be associated with significant side effects. The reasons behind the higher prevalence of TNBC in Mexican women are not fully understood, but genetic factors, environmental influences, and lifestyle factors are all suspected to play a role.
The limited availability of BRCA testing and genetic counseling in Mexico further exacerbates the challenges faced by Mexican women with breast cancer. Genetic testing can identify women at increased risk of developing breast cancer, allowing for proactive measures such as enhanced screening and risk-reducing strategies. For women already diagnosed with breast cancer, BRCA testing can inform treatment decisions, as certain therapies may be more effective for mutation carriers. However, the high cost of genetic testing, often conducted in private labs outside of Mexico, and the lack of public insurance coverage make these crucial services inaccessible to many Mexican women. Addressing these systemic barriers is essential to improving breast cancer outcomes and ensuring equitable healthcare for all women in Mexico.
The Role of BRCA Genes and Triple-Negative Breast Cancer
BRCA1 and BRCA2 are human genes that produce proteins responsible for repairing damaged DNA. They are often referred to as tumor suppressor genes because their normal function helps prevent the development of tumors. Everyone inherits two copies of each of these genes, one from each parent. However, mutations in BRCA1 and BRCA2 can disrupt their normal function, leading to an increased risk of various cancers, most notably breast and ovarian cancers.
Mutations in BRCA genes can be inherited, meaning they are passed down from a parent to their child. If a woman inherits a BRCA mutation, she has a significantly higher lifetime risk of developing breast cancer, ovarian cancer, and other cancers compared to women without these mutations. The risk is particularly elevated for triple-negative breast cancer. Studies have shown that women with BRCA1 mutations are more likely to develop the triple-negative subtype of breast cancer than other subtypes. This strong link between BRCA mutations and TNBC underscores the importance of genetic testing for women diagnosed with this aggressive form of the disease.
Understanding a woman’s BRCA status has significant implications for both treatment and prevention of breast cancer. For women diagnosed with triple-negative breast cancer who carry a BRCA mutation, certain treatment options may be more effective. For example, platinum-based chemotherapy drugs, such as cisplatin, have shown promising results in treating BRCA-mutated TNBC. Furthermore, PARP inhibitors, a newer class of targeted therapies, are specifically designed to target cancer cells with BRCA mutations and have demonstrated efficacy in treating advanced BRCA-mutated breast cancer.
Beyond treatment, BRCA testing plays a crucial role in risk reduction and prevention. Women who are found to carry a BRCA mutation, even if they have not been diagnosed with breast cancer, can consider various risk-reducing strategies. These may include increased breast cancer screening with mammograms and MRIs starting at a younger age, prophylactic mastectomies (surgical removal of the breasts), and prophylactic oophorectomies (surgical removal of the ovaries). These preventative measures can significantly reduce the risk of developing breast and ovarian cancers in BRCA mutation carriers. Therefore, identifying women with BRCA mutations through genetic testing is not only important for personalized treatment but also for proactive risk management and cancer prevention.
Prevalence of BRCA Mutations in Mexican Women: Key Findings
The study focusing on young Mexican women with triple-negative breast cancer revealed a notably high prevalence of BRCA mutations, with 23% of the 190 participants carrying a mutation in either BRCA1 or BRCA2. This finding is significant as it underscores a substantial genetic predisposition to breast cancer within this specific population group. The vast majority of these mutations, 43 out of 44, were found in the BRCA1 gene, highlighting its predominant role in hereditary breast cancer risk among Mexican women.
Further analysis revealed that seven specific BRCA mutations were recurrent, accounting for a remarkable 89% of all mutations detected in the study. This finding points to the existence of founder mutations within the Mexican population, where certain mutations are more common due to historical migration patterns and genetic ancestry. The most frequently observed mutation was a large rearrangement in BRCA1, specifically the deletion of exons 9-12 (ex9-12del). This Mexican founder mutation was identified in 18 cases, representing 41% of all mutations detected in the study. This high frequency of a specific founder mutation has significant implications for genetic testing strategies in Mexico, suggesting that targeted screening for this mutation could be a cost-effective approach.
Other recurrent mutations identified in the study included BRCA1 943ins10, BRCA1 R71G, BRCA1 2925del4, BRCA1 185delAG, BRCA1 R1443X, and BRCA1 3878delTA. Interestingly, some of these mutations are known founder mutations in other populations, reflecting the complex genetic heritage of the Mexican population. For instance, BRCA1 943ins10 is considered an African founder mutation, while BRCA1 R71G is a Spanish founder mutation. The presence of these mutations in Mexican women suggests genetic contributions from both African and European ancestries. The BRCA1 185delAG mutation, a well-known founder mutation in the Ashkenazi Jewish population, was also found in three cases, although none of the women reported Jewish ancestry. This highlights the potential for mutation recurrence across different ethnic groups.
The study also observed a trend of higher mutation prevalence in younger women. Among women diagnosed with triple-negative breast cancer at age 40 or younger, the mutation rate was 30.3%, compared to 18.3% for women diagnosed between ages 41 and 50. This age-related difference further emphasizes the importance of considering BRCA testing for younger women with triple-negative breast cancer in Mexico. The average age of diagnosis was also slightly younger in women with BRCA1 mutations compared to non-carriers, although this difference was not statistically significant.
To provide a clearer picture of the specific mutations and their frequencies, Table 1, adapted from the study data, is presented below:
Table 1: BRCA1 and BRCA2 Mutations Identified in Mexican Women with Triple-Negative Breast Cancer
| Gene | Exon | Mutation | Frequency |
|---|---|---|---|
| BRCA1 | 2 | 185delAG | 3 |
| BRCA1 | 11 | 2415delAG | 1 |
| BRCA1 | 11 | 2925del4 | 4 |
| BRCA1 | 5 | 330A > G (R71G) | 4 |
| BRCA1 | 5 | 3717C > T (Q1200X) | 1 |
| BRCA1 | 11 | 3878delTA | 2 |
| BRCA1 | 13 | 4446C > T (R1443X) | 4 |
| BRCA1 | 18 | 5242C > A (A1708E) | 1 |
| BRCA1 | 11 | 943ins10 | 5 |
| BRCA1 | del exon9-12 | del exon9-12 | 18 |
| BRCA2 | 11 | 2452C > T (Q742X) | 1 |
| Total | 44 |
This table summarizes the specific BRCA mutations found in the study, their location within the gene (exon), the type of mutation, and their frequency among the study participants. The predominance of BRCA1 mutations, particularly the ex9-12del founder mutation, is clearly evident. These findings provide valuable insights into the genetic landscape of breast cancer risk in Mexican women and have important implications for genetic testing and personalized healthcare strategies.
Implications for Healthcare and Genetic Testing in Mexico
The high prevalence of BRCA mutations, particularly BRCA1, in young Mexican women with triple-negative breast cancer has significant implications for healthcare policy and clinical practice in Mexico. The study’s findings strongly support the need to expand access to BRCA testing for this high-risk population. Given the 23% mutation rate, routine BRCA testing for all young women diagnosed with triple-negative breast cancer in Mexico could identify a substantial number of mutation carriers who could benefit from tailored treatment and risk-reduction strategies.
Current guidelines in many developed countries recommend BRCA testing for women with triple-negative breast cancer, particularly those diagnosed at a younger age. However, in Mexico, the lack of widespread availability and affordability of genetic testing presents a significant barrier to implementing these recommendations. The study’s results provide compelling evidence to advocate for increased public funding and insurance coverage for BRCA testing in Mexico, especially for women with triple-negative breast cancer.
The identification of the Mexican founder mutation, BRCA1 ex9-12del, also offers an opportunity to implement cost-effective targeted genetic screening strategies. Screening specifically for this founder mutation, along with other recurrent mutations identified in the study, could significantly reduce the cost and complexity of genetic testing compared to full gene sequencing. The HISPANEL assay, a panel of 115 recurrent BRCA mutations prevalent in Hispanic women, including the Mexican founder mutation, offers a practical and affordable tool for targeted mutation screening in Mexico. The study estimates that HISPANEL can detect approximately 68% of BRCA mutations in Mexican women with breast cancer, making it a valuable first-line screening approach.
Expanding access to genetic counseling is equally crucial alongside increased BRCA testing. Genetic counseling provides women with the necessary information and support to understand their genetic test results, make informed decisions about treatment and risk reduction, and address the emotional and psychological impact of carrying a BRCA mutation. Developing and integrating genetic counseling services within the Mexican healthcare system is essential to ensure that women receive comprehensive and patient-centered care.
The study’s findings also have implications for treatment decisions for Mexican women with triple-negative breast cancer. Identifying BRCA mutation carriers allows for personalized treatment approaches, including the consideration of platinum-based chemotherapy and PARP inhibitors. Furthermore, BRCA status can inform decisions about surgery, such as the choice between lumpectomy and mastectomy, and the potential benefit of contralateral prophylactic mastectomy (removal of the healthy breast to reduce the risk of developing cancer in the other breast). For women who are not diagnosed with breast cancer but are found to carry a BRCA mutation, genetic counseling can guide decisions about risk-reducing strategies, such as prophylactic mastectomies and oophorectomies, and enhanced breast cancer screening.
Study Limitations and Future Directions
While this study provides valuable insights into the prevalence of BRCA mutations in young Mexican women with triple-negative breast cancer, it is important to acknowledge its limitations. The study utilized the HISPANEL assay, which screens for a panel of recurrent mutations but does not encompass full gene sequencing of BRCA1 and BRCA2. Therefore, the study may have underestimated the true prevalence of BRCA mutations, as rare or novel mutations not included in the HISPANEL panel would not have been detected. The authors estimate that HISPANEL identifies approximately 68% of all BRCA mutations in Mexican women, suggesting that full gene sequencing could potentially reveal an even higher mutation prevalence.
The study was conducted at a single cancer center in Mexico City, which may limit the generalizability of the findings to the broader Mexican population. The prevalence and distribution of BRCA mutations may vary across different regions of Mexico due to genetic diversity and founder effects. Future studies should include a more geographically diverse sample of Mexican women to provide a more comprehensive understanding of BRCA mutation prevalence across the country.
Another limitation is the retrospective nature of the study and the potential for survivorship bias. The study included women diagnosed with triple-negative breast cancer between 2006 and 2012, and genetic testing was conducted on prevalent cases, with an average of six years passing between diagnosis and testing. Women with BRCA mutations may have a poorer prognosis and shorter survival compared to non-carriers. If this is the case, the study may have underrepresented women with BRCA mutations who died before being included in the study, potentially leading to an underestimation of the true mutation prevalence. Future studies should ideally be prospective, enrolling women at the time of diagnosis, to minimize survivorship bias.
Despite these limitations, this study provides a crucial foundation for future research and healthcare improvements for Mexican women with breast cancer. Future research should focus on full gene sequencing of BRCA1 and BRCA2 in larger and more diverse cohorts of Mexican women to identify the full spectrum of BRCA mutations and refine prevalence estimates. Investigating the clinical and pathological characteristics of BRCA-mutated breast cancers in Mexican women, as well as their response to different treatments, is also essential. Furthermore, research is needed to address the barriers to BRCA testing and genetic counseling in Mexico and to develop culturally tailored interventions to improve access to these crucial services. Finally, studies exploring the cost-effectiveness of different genetic testing strategies and risk-reduction interventions in the Mexican context are needed to inform healthcare policy and resource allocation decisions.
Conclusion
This study unequivocally demonstrates a high prevalence of BRCA1 mutations in young Mexican women diagnosed with triple-negative breast cancer. The 23% mutation rate, with BRCA1 mutations predominating, underscores a significant genetic contribution to breast cancer risk in this population. The identification of the Mexican founder mutation, BRCA1 ex9-12del, and other recurrent mutations provides valuable insights into the genetic landscape of breast cancer in Mexican women and offers opportunities for targeted genetic screening strategies.
The findings of this research carry a clear and urgent message: BRCA testing is essential for young Mexican women with triple-negative breast cancer. Expanding access to affordable and comprehensive genetic testing and counseling services is paramount to improving healthcare outcomes for this high-risk population. By identifying BRCA mutation carriers, healthcare providers can offer personalized treatment approaches, guide risk-reduction strategies, and extend testing to at-risk family members. This proactive approach to genetic testing and personalized medicine holds the promise of reducing breast cancer morbidity and mortality among Mexican women. It is imperative that healthcare systems and policymakers in Mexico prioritize and invest in expanding access to genetic services to ensure that all women, regardless of their socioeconomic status or geographic location, can benefit from these life-saving advances in breast cancer care.
References
[1] Romieu I, Lazcano-Ponce E, Velázquez-Cruz R, et al. Breast cancer mortality in Latin America and the Caribbean: an ecological study. Salud Publica Mex. 2004;46(2):126-33.
[2] Secretaría de Salud. Estadísticas de mortalidad general, México 2010. México, D.F.: Secretaría de Salud; 2011.
[3] Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al. Challenges to effective cancer control in Latin America and the Caribbean–a report from the Global Task Force on Expanded Access to Cancer Care in Developing Countries. Lancet Oncol. 2013;14(4):381-95.
[4] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
[5] Linares-Gonzalez LM, Perez-Plasencia C, Soto-Perez-de-Celis E, et al. Clinical and pathological differences between early-onset and late-onset breast cancer in Mexican women. J Surg Oncol. 2012;106(7):715-20.
[6] Ruiz-Wieland E, Bardelli-Evans E, Peñaloza-González JG, et al. Breast cancer in Mexico: a 10 year analysis at a single institution. J Surg Oncol. 2008;97(7):569-73.
[7] Uribe C, Villarreal C, Moreno F, et al. Pathological and immunohistochemical features of breast cancer in Mexico. Breast J. 2008;14(5):438-45.
[8] Villarreal-Garza C, Aguila-Mejia P, Ramirez-Ugalde T, et al. Breast cancer in young women in Mexico: a comparative analysis with older women. J Surg Oncol. 2013;107(7):719-24.
[9] Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34.
[10] Diez O, Alonso MC, Andrés R, et al. Spectrum of germline BRCA1 and BRCA2 mutations in Spanish families with breast and/or ovarian cancer. Breast Cancer Res Treat. 2003;80(1):49-59.
[11] Echeverry M, García-Gómez R, Vesga MA, et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Colombia. Breast Cancer Res Treat. 2012;133(2):645-54.
[12] Gutiérrez-Enríquez S, de la Hoya M, Pollán M, et al. Evaluation of the contribution of BRCA1 and BRCA2 Spanish founder mutations to breast cancer in Spain. Hum Mutat. 2000;16(6):482-6.
[13] Torres D, Rashid MU, Gil F, et al. High proportion of BRCA1/2 founder mutations in unselected breast cancer patients from Colombia. Breast Cancer Res Treat. 2007;103(2):225-32.
[14] Teixeira N, Pinto P, Santos C, et al. Prevalence of BRCA1 and BRCA2 germline mutations in Portuguese women with early-onset breast cancer. Breast Cancer Res Treat. 2006;95(3):203-10.
[15] Baez-Vega KM, Palacio IS, Moreno G, et al. Prevalence of BRCA1 mutations in unselected breast cancer patients from Puerto Rico. Cancer Genet Cytogenet. 2009;190(1):49-54.
[16] Garre P, Gutierrez S, Diez O, et al. BRCA1 and BRCA2 mutations in breast cancer patients from Uruguay. Breast Cancer Res Treat. 2005;90(3):271-7.
[17] Liede A, Karlan BY, Narod SA. Cancer risks for BRCA1 and BRCA2 mutation carriers: implications for cancer prevention. J Clin Oncol. 2000;18(6):1361-9.
[18] Villarreal-Garza C, Weitzel JN, Llacuachaqui M, et al. The prevalence of BRCA1 and BRCA2 mutations among young women with triple-negative breast cancer in Mexico. Breast Cancer Res Treat. 2013;138(2):455-61.
[19] Villarreal-Garza C, Estrada-Mena N, Perez-Santos M, et al. Prevalence of BRCA1 and BRCA2 mutations in multiple case breast cancer families from Mexico. Cancer Genet Cytogenet. 2010;203(2):227-32.
[20] Volcjak J, Niemiec T, Plisiecka-Haluch A, et al. Founder mutations in BRCA1 and BRCA2 genes account for a significant proportion of mutations in Polish families with breast and/or ovarian cancer. Int J Cancer. 2005;113(6):913-8.
[21] Yoshihara M, Castro FA, Masukawa KY, et al. Prevalence of BRCA1 and BRCA2 mutations in Brazilian women with breast cancer. Cancer Genet Cytogenet. 2007;179(2):123-30.
[22] Warner E, Foulkes WD, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in women with breast cancer. J Natl Cancer Inst. 1999;91(17):1482-8.
[23] Weitzel JN, Lagos VI, Cullinane CA, et al. Limited BRCA1 and BRCA2 mutations in unselected women of Mexican descent with breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(2):443-9.
[24] Weitzel JN, Lagos V, Cullinane C, et al. BRCA1 founder mutations in Latinas with breast cancer. Breast Cancer Res Treat. 2005;90(2):117-26.
[25] Weitzel JN, Mendoza R, Lagos V, et al. Breast and ovarian cancer in women of Mexican descent: the clinical impact of novel BRCA1 mutations. Genet Test. 2003;7(4):295-303.
[26] Abkevich V, Zharkov A, Bezlepkina O, et al. Founder effect of breast/ovarian cancer-predisposing BRCA1 mutations in Slavic populations. Am J Hum Genet. 1995;57(2):306-15.
[27] Blanco AM, López-Perolio I, Sanz DJ, et al. Founder mutations in BRCA1 and BRCA2 genes in Spanish families with breast and ovarian cancer. Clin Genet. 2006;69(4):342-9.
[28] Chappuis PO, Vaur D, Lidereau R. Founder mutations in the BRCA1 gene. Genet Couns. 1999;10(1):1-12.
[29] Gayther SA, Warren W, Mazoyer S, et al. Germline mutations in the BRCA1 gene in breast and ovarian cancer families from Western Europe. Am J Hum Genet. 1995;56(3):769-76.
[30] Friedman E, Kaufman B, Eisinger F, et al. Founder BRCA1 and BRCA2 mutations in Israel. Breast Cancer Res Treat. 2003;80(1):33-40.
[31] Neuhausen SL, Mazoyer S, Friedman LS, et al. Haplotype and phenotype analysis of nine recurrent BRCA1 mutations in 1,100 individuals: results of an international study. Am J Hum Genet. 1996;58(2):271-80.
[32] Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91(11):943-9.
[33] Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996;13(1):117-9.
[34] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. Version 2.2013. Fort Washington, PA: NCCN; 2013.
[35] De La Hoya M, Caldés T, Liefers GJ, et al. A prevalent founder BRCA1 mutation in families of Dutch origin. Br J Cancer. 2003;88(2):264-7.
[36] Fackenthal JD, Olopade OI. Breast cancer genetics: BRCA1 and BRCA2 mutations and racial disparity. Fam Cancer. 2005;4(1):1-8.
[37] উনিভার্সিটি অফ পেনসিলভানিয়া। Breast Cancer Information Core (BIC). http://research.nhgri.nih.gov/projects/bic/Member/index.shtml. Accessed 15 Aug 2012.
[38] Domchek SM, Weber BL. Clinical significance of BRCA1 and BRCA2 mutations. J Clin Oncol. 2004;22(2):374-84.
[39] Casilli F, Radice P, Peterlongo P, et al. Founder mutations in the BRCA1 gene: geographical distribution and prevalence in Southern Europe. Ann Oncol. 2000;11(11):1395-403.
[40] Castilla LH, Couch FJ, Erdos D, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet. 1994;8(4):387-91.
[41] Friedman E, Fodor D, Zidan J, et al. Founder mutations in the BRCA1 and BRCA2 genes among Ashkenazi Jews with breast and ovarian cancer. Am J Hum Genet. 1997;60(5):1013-23.
[42] Robledo M, Clavel C, Caldés T, et al. BRCA1 mutations in Spanish breast cancer families. Int J Cancer. 1997;70(6):704-9.
[43] Weitzel JN, Blazer KR, MacDonald DJ, et al. Genetics, ethnicity, and cancer risk: disparities and directions for research and clinical practice. JAMA. 2011;305(17):1731-2.
[44] Gonzalez-Angulo AM, Timms KM, Liu S, et al. Triple-negative breast cancer with BRCA1 mutation: prognostic implications. Cancer Res. 2011;71(11):3835-46.
[45] Rakha EA, Tan DS, Foulkes WD, et al. Are triple-negative breast cancers and BRCA1-related breast cancers one and the same? Breast Cancer Res. 2009;11(5):R67.
[46] схিমিত্রিয়াডৌ এ, গুরলিঞ্জি জে, এস্টেল্লা পিজে, এট আল। BRCA1 এবং BRCA2 মিউটেশন এবং ট্রিপল-নেগেটিভ ব্রেস্ট ক্যান্সার: একটি পদ্ধতিগত পর্যালোচনা এবং মেটা-বিশ্লেষণ। J Natl Cancer Inst. 2010;102(13):952-69.
[47] Tutt A, Tutt AN, Barrett S, et al. Adjuvant and neoadjuvant platinums in early breast cancer: meta-analysis of the randomized controlled trials. J Clin Oncol. 2011;29(15_suppl):1005.
[48] Byrski T, Nadzieja D, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant cisplatin. Breast Cancer Res Treat. 2012;135(1):243-50.
[49] Huzarski T, Gronwald J, Byrski T, et al. Bilateral oophorectomy reduces mortality in BRCA1 mutation carriers with breast cancer. J Clin Oncol. 2013;31(1):1-7.
[50] Metcalfe KA, Lynch HT, Ghadirian P, et al. Contralateral mastectomy reduces breast cancer mortality in women with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(14):2215-20.
